跳至主要内容
临床试验/JPRN-UMIN000023657
JPRN-UMIN000023657已完成未知

Study of the efficacy of sucroferric oxyhydroxide (chewable tablet) on the control of CKD-MBD and improvement of renal anemia in hemodialysis patients with hyperphosphatemia. - Study of the efficacy of sucroferric oxyhydroxide (chewable tablet) on the control of CKD-MBD and improvement of renal anemia in hemodialysis patients with hyperphosphatemia.

Kawashima Hospital, Social Medical Corporation Kawashima Hospital Group0 个研究点目标入组 50 人开始时间: 2016年8月17日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Patients with a serum ferritin level of 300 ng/mL or more at the latest examination prior to entry 2)Patients with a history of hypersensitivity to the ingredients of sucroferric oxyhydroxide (chewable tablet) 3)Patients who are or may be pregnant or are breast-feeding 4)Patients who are considered inappropriate for participation in this study by the investigator's judgment

研究者

发起方
Kawashima Hospital, Social Medical Corporation Kawashima Hospital Group

相似试验